Premium
Current treatment strategies for advanced prostate cancer
Author(s) -
Komura Kazumasa,
Sweeney Christopher J,
Inamoto Teruo,
Ibuki Naokazu,
Azuma Haruhito,
Kantoff Philip W
Publication year - 2018
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.13512
Subject(s) - medicine , enzalutamide , cabazitaxel , prostate cancer , oncology , radium 223 , abiraterone , randomized controlled trial , cancer , androgen deprivation therapy , androgen receptor , bone metastasis
During the past decade, treatment strategies for patients with advanced prostate cancer involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent prostate cancer after treatment with curative intent, as well as castration‐resistant prostate cancer, have extensively evolved with the introduction and approval of several new agents including sipuleucel‐T, radium‐223, abiraterone, enzalutamide and cabazitaxel, all of which have shown significant improvement on overall survival. The appropriate use of these agents and the proper sequencing of these agents are still not optimized. The results of several recently reported randomized controlled trials and retrospective studies could assist in developing a treatment strategy for advanced prostate cancer . In addition, prospective studies and molecular characterization of tumors to address these issues are ongoing.